New drug cocktail aims to fight advanced cervical cancer
NCT ID NCT04982237
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial is testing whether adding the immunotherapy AK104 to standard chemotherapy (with or without bevacizumab) helps people with advanced cervical cancer that cannot be cured by surgery or radiation. About 445 participants will receive either the drug combo or a placebo. The main goals are to see if the treatment slows cancer growth and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK104 (a type of immunotherapy) plus chemotherapy (paclitaxel, carboplatin, or cisplatin) with or without bevacizumab
What this could lead to
If successful, this could offer a new first-line treatment option that helps people with advanced cervical cancer live longer and delay disease progression.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet confirmed. The treatment may not work better than standard care, and side effects from the combination therapy could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital
Hefei, China
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
-
The Second Affiliated Hospital,Anhui Medical University
Hefei, China
-
Women's Hospital School Of Medicine Zhejiang University
Hangzhou, China
-
Zhejiang Cancer Hospital
Hangzhou, China